<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37279956</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2157-6580</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>14</Day></PubDate></JournalIssue><Title>Stem cells translational medicine</Title><ISOAbbreviation>Stem Cells Transl Med</ISOAbbreviation></Journal><ArticleTitle>Allogenic Umbilical Cord-Derived Mesenchymal Stromal Cells Sustain Long-Term Therapeutic Efficacy Compared With Low-Dose Interleukin-2 in Systemic Lupus Erythematosus.</ArticleTitle><Pagination><StartPage>431</StartPage><EndPage>443</EndPage><MedlinePgn>431-443</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/stcltm/szad032</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Mesenchymal stromal cells (MSCs) and low-dose interleukin-2 (IL-2) both have demonstrated efficacy in treating systemic lupus erythematosus (SLE). The aim of this study is to conduct a head-to-head comparison between the 2 treatments and provide insights for clinical applications.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Lupus-prone mice were treated with umbilical cord-derived MSCs (UC-MSCs), IL-2, or a combination of UC-MSCs and IL-2, respectively. The lupus-like symptoms, renal pathology, and T-cell response were assessed 1 or 4 weeks later. Modulation of IL-2 production by MSCs on immune cells was investigated by the coculture assay. Disease activity and serum IL-2 of SLE patients were determined before and after receiving UC-MSCs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Both UC-MSCs and IL-2 improved lupus symptoms in lupus-prone mice 1 week after treatment, while the effects of UC-MSCs lasted up to 4 weeks. Moreover, the UC-MSC-treated group showed better renal pathology improvement. Importantly, UC-MSCs combined with IL-2 did not provide better efficacy than UC-MSCs alone. Consistent with this, UC-MSCs alone and UC-MSCs&#x2005;+&#x2005;IL-2 resulted in similar levels of serum IL-2 and frequencies of Tregs. Neutralization of IL-2 partly reduced the promotion of Tregs by UC-MSCs, suggesting that IL-2 was involved in the upregulation of Tregs by UC-MSCs. Lastly, an increase in serum IL-2 positively correlated with the reduction of disease activity of SLE patients by UC-MSCs.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Both the single injection of UC-MSCs and repeated IL-2 administration exerted comparable efficacy in alleviating SLE manifestations, but UC-MSCs provided sustained alleviation and showed better improvement in renal pathology.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Zhouli</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-0822-2447</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>DanDan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jing</LastName><ForeName>Lijuan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Wenjuan</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nanjing Drum Tower Hospital of China Pharmaceutical University, Jiangsu, Nanjing, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xueyi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nanjing Drum Tower Hospital of China Pharmaceutical University, Jiangsu, Nanjing, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Ziyi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Nanjing Drum Tower Hospital of China Pharmaceutical University, Jiangsu, Nanjing, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Genhong</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Weiwei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Xiaojun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geng</LastName><ForeName>Linyu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaojing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Shuai</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Xuebing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Huayong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shanshan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Wenchao</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Lingyun</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nanjing Drum Tower Hospital of China Pharmaceutical University, Jiangsu, Nanjing, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2020YFA0710800</GrantID><Agency>National Key Research and Development Program of China</Agency><Country/></Grant><Grant><GrantID>81930043</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>SWYY-167</GrantID><Agency>Jiangsu Province Six Talent Project</Agency><Country/></Grant><Grant><GrantID>81720108020</GrantID><Agency>Major International (Regional) Joint Research Project of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Stem Cells Transl Med</MedlineTA><NlmUniqueID>101578022</NlmUniqueID><ISSNLinking>2157-6564</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Stem Cells Transl Med. 2023 Jun 29;:</RefSource><PMID Version="1">37382548</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018920" MajorTopicYN="N">Coculture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059630" MajorTopicYN="Y">Mesenchymal Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014470" MajorTopicYN="N">Umbilical Cord</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045164" MajorTopicYN="Y">Mesenchymal Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">interleukin-2</Keyword><Keyword MajorTopicYN="N">mesenchymal stromal cells</Keyword><Keyword MajorTopicYN="N">regulatory T cells</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors declared no potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>7</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>6</Day><Hour>20</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37279956</ArticleId><ArticleId IdType="pmc">PMC10346415</ArticleId><ArticleId IdType="doi">10.1093/stcltm/szad032</ArticleId><ArticleId IdType="pii">7190821</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fava A, Petri M.. Systemic lupus erythematosus: diagnosis and clinical management. J Autoimmun. 2019;96:1-13. 10.1016/j.jaut.2018.11.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2018.11.001</ArticleId><ArticleId IdType="pmc">PMC6310637</ArticleId><ArticleId IdType="pubmed">30448290</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110-2121. 10.1056/NEJMra1100359</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1100359</ArticleId><ArticleId IdType="pubmed">22129255</ArticleId></ArticleIdList></Reference><Reference><Citation>Merimi M, Lewalle P, Meuleman N, et al. . Mesenchymal stem/stromal cell therapeutic features: the bridge between the bench and the clinic. J Clin Med. 2021;10(5):905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7956428</ArticleId><ArticleId IdType="pubmed">33668878</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Tian M, Wang F, et al. . Understanding the immunological mechanisms of mesenchymal stem cells in allogeneic transplantation: from the aspect of major histocompatibility complex class I. Stem Cells Dev. 2019;28(17):1141-1150. 10.1089/scd.2018.0256</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/scd.2018.0256</ArticleId><ArticleId IdType="pubmed">31215341</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Li J, Zhang Y, et al. . Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Res Ther. 2014;16(2):R79. 10.1186/ar4520</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar4520</ArticleId><ArticleId IdType="pmc">PMC4060570</ArticleId><ArticleId IdType="pubmed">24661633</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Wang D, Liang J, et al. . Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum. 2010;62(8):2467-2475. 10.1002/art.27548</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27548</ArticleId><ArticleId IdType="pubmed">20506343</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Zhang H, Liang J, et al. . Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. Cell Transplant. 2013;22(12):2267-2277. 10.3727/096368911X582769c</Citation><ArticleIdList><ArticleId IdType="doi">10.3727/096368911X582769c</ArticleId><ArticleId IdType="pubmed">24388428</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou T, Li HY, Liao C, Lin W, Lin S.. Clinical efficacy and safety of mesenchymal stem cells for systemic lupus erythematosus. Stem Cells Int. 2020;2020:6518508. 10.1155/2020/6518508</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/6518508</ArticleId><ArticleId IdType="pmc">PMC7157802</ArticleId><ArticleId IdType="pubmed">32322279</ArticleId></ArticleIdList></Reference><Reference><Citation>Baiguera S, Jungebluth P, Mazzanti B, Macchiarini P.. Mesenchymal stromal cells for tissue-engineered tissue and organ replacements. Transpl Int. 2012;25(4):369-382. 10.1111/j.1432-2277.2011.01426.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1432-2277.2011.01426.x</ArticleId><ArticleId IdType="pubmed">22248229</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohl K, Tenbrock K.. Regulatory T cells in systemic lupus erythematosus. Eur J Immunol. 2015;45(2):344-355. 10.1002/eji.201344280</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201344280</ArticleId><ArticleId IdType="pubmed">25378177</ArticleId></ArticleIdList></Reference><Reference><Citation>Uccelli A, de Rosbo NK.. The immunomodulatory function of mesenchymal stem cells: mode of action and pathways. Ann N Y Acad Sci. 2015;1351:114-126. 10.1111/nyas.12815</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nyas.12815</ArticleId><ArticleId IdType="pubmed">26152292</ArticleId></ArticleIdList></Reference><Reference><Citation>Doyle EC, Wragg NM, Wilson SL.. Intraarticular injection of bone marrow-derived mesenchymal stem cells enhances regeneration in knee osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 2020;28(12):3827-3842. 10.1007/s00167-020-05859-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00167-020-05859-z</ArticleId><ArticleId IdType="pmc">PMC7669782</ArticleId><ArticleId IdType="pubmed">32006075</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez MA, Gonzalez-Rey E, Rico L, B&#xfc;scher D, Delgado M.. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology. 2009;136(3):978-989. 10.1053/j.gastro.2008.11.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2008.11.041</ArticleId><ArticleId IdType="pubmed">19135996</ArticleId></ArticleIdList></Reference><Reference><Citation>Court AC, Le-Gatt A, Luz-Crawford P, et al. . Mitochondrial transfer from mscs to T cells induces treg differentiation and restricts inflammatory response. EMBO Rep. 2020;21(2):e48052. 10.15252/embr.201948052</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.201948052</ArticleId><ArticleId IdType="pmc">PMC7001501</ArticleId><ArticleId IdType="pubmed">31984629</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyagawa I, Nakayamada S, Nakano K, et al. . Induction of regulatory T cells and its regulation with insulin-like growth factor/insulin-like growth factor binding protein-4 by human mesenchymal stem cells. The Journal of Immunology. 2017;199(5):1616-1625. 10.4049/jimmunol.1600230</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1600230</ArticleId><ArticleId IdType="pubmed">28724578</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Ni B, Liu Q, et al. . Human umbilical cord-derived mesenchymal stem cells ameliorate experimental colitis by normalizing the gut microbiota. Stem Cell Res Ther. 2022;13(1):475. 10.1186/s13287-022-03118-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-022-03118-1</ArticleId><ArticleId IdType="pmc">PMC9476645</ArticleId><ArticleId IdType="pubmed">36104756</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizui M, Tsokos GC.. Low-dose Il-2 in the treatment of lupus. Curr Rheumatol Rep. 2016;18(11):68.</Citation><ArticleIdList><ArticleId IdType="pubmed">27734211</ArticleId></ArticleIdList></Reference><Reference><Citation>Koreth J, Matsuoka K, Kim HT, et al. . Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365(22):2055-2066. 10.1056/NEJMoa1108188</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1108188</ArticleId><ArticleId IdType="pmc">PMC3727432</ArticleId><ArticleId IdType="pubmed">22129252</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman LA, Tsokos GC.. The Il-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity. J Biomed Biotechnol. 2010;2010:740619. 10.1155/2010/740619</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2010/740619</ArticleId><ArticleId IdType="pmc">PMC2896881</ArticleId><ArticleId IdType="pubmed">20625413</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos GC, Lo MS, Costa Reis P, Sullivan KE.. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12(12):716-730. 10.1038/nrrheum.2016.186</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2016.186</ArticleId><ArticleId IdType="pubmed">27872476</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Zhang R, Shao M, et al. . Efficacy and safety of low-dose Il-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2020;79(1):141-149. 10.1136/annrheumdis-2019-215396</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215396</ArticleId><ArticleId IdType="pmc">PMC6937406</ArticleId><ArticleId IdType="pubmed">31537547</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, Zhang X, Su L, et al. . Fine tuning subsets of Cd4(+) T cells by low-dosage of Il-2 and a new therapeutic strategy for autoimmune diseases. Int Immunopharmacol. 2018;56:269-276. 10.1016/j.intimp.2018.01.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2018.01.042</ArticleId><ArticleId IdType="pubmed">29414661</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Zhang X, Wei Y, et al. . Low-dose interleukin-2 treatment selectively modulates Cd4(+) T cell subsets in patients with systemic lupus erythematosus. Nat Med. 2016;22(9):991-993. 10.1038/nm.4148</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4148</ArticleId><ArticleId IdType="pubmed">27500725</ArticleId></ArticleIdList></Reference><Reference><Citation>de Porto AP, Lammers AJ, Bennink RJ, et al. . Assessment of splenic function. Eur J Clin Microbiol Infect Dis. 2010;29(12):1465-1473. 10.1007/s10096-010-1049-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-010-1049-1</ArticleId><ArticleId IdType="pmc">PMC2995208</ArticleId><ArticleId IdType="pubmed">20853172</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Xu X, Ran M, et al. . The enlargement of abdominal lymph nodes is a characteristic of autoimmune liver disease. Mediators Inflamm. 2020;2020:3631625. 10.1155/2020/3631625</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/3631625</ArticleId><ArticleId IdType="pmc">PMC7115048</ArticleId><ArticleId IdType="pubmed">32273828</ArticleId></ArticleIdList></Reference><Reference><Citation>Karnopp TE, Chapacais GF, Freitas EC, Monticielo OA.. Lupus animal models and neuropsychiatric implications. Clin Rheumatol. 2021;40(7):2535-2545. 10.1007/s10067-020-05493-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-020-05493-7</ArticleId><ArticleId IdType="pubmed">33155159</ArticleId></ArticleIdList></Reference><Reference><Citation>Chasset F, Arnaud L.. Targeting interferons and their pathways in systemic lupus erythematosus. Autoimmun Rev. 2018;17(1):44-52. 10.1016/j.autrev.2017.11.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2017.11.009</ArticleId><ArticleId IdType="pubmed">29108825</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrat FJ, Crow MK, Ivashkiv LB.. Interferon target-gene expression and epigenomic signatures in health and disease. Nat Immunol. 2019;20(12):1574-1583. 10.1038/s41590-019-0466-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-019-0466-2</ArticleId><ArticleId IdType="pmc">PMC7024546</ArticleId><ArticleId IdType="pubmed">31745335</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer SS, Cheng G.. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol. 2012;32(1):23-63. 10.1615/critrevimmunol.v32.i1.30</Citation><ArticleIdList><ArticleId IdType="doi">10.1615/critrevimmunol.v32.i1.30</ArticleId><ArticleId IdType="pmc">PMC3410706</ArticleId><ArticleId IdType="pubmed">22428854</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou MG, Dasgupta A, Ward MM.. Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: a systematic review and Bayesian meta-analysis. Arthritis Rheumatol. 2016;68(6):1432-1441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5071782</ArticleId><ArticleId IdType="pubmed">26815601</ArticleId></ArticleIdList></Reference><Reference><Citation>Robak E, Niewiadomska H, Robak T, et al. . Lymphocyctes Tgammadelta in clinically normal skin and peripheral blood of patients with systemic lupus erythematosus and their correlation with disease activity. Mediators Inflamm. 2001;10(4):179-189. 10.1080/09629350124724</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09629350124724</ArticleId><ArticleId IdType="pmc">PMC1781712</ArticleId><ArticleId IdType="pubmed">11577994</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimoto S, Tokano Y, Kaneko H, et al. . The increased interleukin-13 in patients with systemic lupus erythematosus: relations to other Th1-, Th2-related cytokines and clinical findings. Autoimmunity. 2001;34(1):19-25. 10.3109/08916930108994122</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08916930108994122</ArticleId><ArticleId IdType="pubmed">11681489</ArticleId></ArticleIdList></Reference><Reference><Citation>Duffy MM, Ritter T, Ceredig R, Griffin MD.. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther. 2011;2(4):34. 10.1186/scrt75</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/scrt75</ArticleId><ArticleId IdType="pmc">PMC3219065</ArticleId><ArticleId IdType="pubmed">21861858</ArticleId></ArticleIdList></Reference><Reference><Citation>von Spee-Mayer C, Siegert E, Abdirama D, et al. . Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann Rheum Dis. 2016;75(7):1407-1415. 10.1136/annrheumdis-2015-207776</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-207776</ArticleId><ArticleId IdType="pubmed">26324847</ArticleId></ArticleIdList></Reference><Reference><Citation>Humrich JY, Riemekasten G.. Low-dose interleukin-2 therapy for the treatment of systemic lupus erythematosus. Curr Opin Rheumatol. 2019;31(2):208-212. 10.1097/BOR.0000000000000575</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000575</ArticleId><ArticleId IdType="pubmed">30562181</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Fu L, Liang Y, et al. . Exosomes originating from Mscs stimulated with Tgf-&#x392; and Ifn-&#x393; promote Treg differentiation. J Cell Physiol. 2018;233(9):6832-6840. 10.1002/jcp.26436</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.26436</ArticleId><ArticleId IdType="pubmed">29336475</ArticleId></ArticleIdList></Reference><Reference><Citation>Kronbichler A, Brezina B, Gauckler P, et al. . Refractory lupus nephritis: when, why and how to treat. Autoimmun Rev. 2019;18(5):510-518.</Citation><ArticleIdList><ArticleId IdType="pubmed">30844548</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenzwajg M, Lorenzon R, Cacoub P, et al. . Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis. 2019;78(2):209-217. 10.1136/annrheumdis-2018-214229</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214229</ArticleId><ArticleId IdType="pubmed">30472651</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson LB, Bell CJM, Howlett SK, et al. . A long-lived Il-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease. J Autoimmun. 2018;95:1-14. 10.1016/j.jaut.2018.10.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2018.10.017</ArticleId><ArticleId IdType="pmc">PMC6284106</ArticleId><ArticleId IdType="pubmed">30446251</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Sun J, Wang Y, et al. . Site-specific pegylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells. Nat Biomed Eng. 2021;5(11):1288-1305. 10.1038/s41551-021-00797-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41551-021-00797-8</ArticleId><ArticleId IdType="pubmed">34580438</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang JH, Cutler AJ, Ferreira RC, et al. . Natural variation in interleukin-2 sensitivity influences regulatory T-cell frequency and function in individuals with long-standing type 1 diabetes. Diabetes. 2015;64(11):3891-3902. 10.2337/db15-0516</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db15-0516</ArticleId><ArticleId IdType="pmc">PMC4975524</ArticleId><ArticleId IdType="pubmed">26224887</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang J, Zhang H, Hua B, et al. . Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis. 2010;69(8):1423-1429. 10.1136/ard.2009.123463</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2009.123463</ArticleId><ArticleId IdType="pubmed">20650877</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan G-p, Yao X, Yang S-j, et al. . Transplanted human umbilical cord mesenchymal stem cells facilitate lesion repair in b6.FAS mice. Journal of Immunology Research. 2014;20141530501-1530513. 10.1155/2014/530501</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/530501</ArticleId><ArticleId IdType="pmc">PMC4352485</ArticleId><ArticleId IdType="pubmed">25759830</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng D, Zhang P, Guo Y, Lim TO.. A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis. Ann Rheum Dis. 2017;76(8):1436-1439. 10.1136/annrheumdis-2017-211073</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-211073</ArticleId><ArticleId IdType="pubmed">28478399</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng X, Che N, Liu Y, et al. . Restored immunosuppressive effect of mesenchymal stem cells on B cells after olfactory 1/early B cell factor-associated zinc-finger protein down-regulation in patients with systemic lupus erythematosus. Arthritis Rheumatol 2014;66(12):3413-3423. 10.1002/art.38879</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38879</ArticleId><ArticleId IdType="pubmed">25219468</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor EB, Sasser JM, Maeda KJ, Ryan MJ.. Expansion of regulatory T cells using low-dose interleukin-2 attenuates hypertension in an experimental model of systemic lupus erythematosus. Am J Physiol Renal Physiol. 2019;317(5):F1274-F1284. 10.1152/ajprenal.00616.2018</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajprenal.00616.2018</ArticleId><ArticleId IdType="pmc">PMC6879936</ArticleId><ArticleId IdType="pubmed">30892934</ArticleId></ArticleIdList></Reference><Reference><Citation>Matta BM, Lott JM, Mathews LR, et al. . Il-33 Is an unconventional alarmin that stimulates Il-2 secretion by dendritic cells to selectively expand Il-33r/St2+ regulatory T cells. J Immunol. 2014;193(8):4010-4020. 10.4049/jimmunol.1400481</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1400481</ArticleId><ArticleId IdType="pmc">PMC4185240</ArticleId><ArticleId IdType="pubmed">25217167</ArticleId></ArticleIdList></Reference><Reference><Citation>Rana BMJ, Jou E, Barlow JL, et al. . A stromal cell niche sustains Ilc2-mediated type-2 conditioning in adipose tissue. J Exp Med. 2019;216(9):1999-2009. 10.1084/jem.20190689</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20190689</ArticleId><ArticleId IdType="pmc">PMC6719433</ArticleId><ArticleId IdType="pubmed">31248899</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L, Leijten J, van Blitterswijk CA, Karperien M.. Fibroblast growth factor-1 is a mesenchymal stromal cell-secreted factor stimulating proliferation of osteoarthritic chondrocytes in co-culture. Stem Cells Dev. 2013;22(17):2356-2367. 10.1089/scd.2013.0118</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/scd.2013.0118</ArticleId><ArticleId IdType="pmc">PMC3749707</ArticleId><ArticleId IdType="pubmed">23557133</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Hsu HC, Stockard CR, et al. . Il-12 inhibits thymic involution by enhancing Il-7- and Il-2-induced thymocyte proliferation. J Immunol. 2004;172(5):2909-2916. 10.4049/jimmunol.172.5.2909</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.172.5.2909</ArticleId><ArticleId IdType="pubmed">14978093</ArticleId></ArticleIdList></Reference><Reference><Citation>Bollyky PL, Falk BA, Long SA, et al. . Cd44 costimulation promotes Foxp3+ regulatory T cell persistence and function via production of Il-2, Il-10, and Tgf-beta. J Immunol. 2009;183(4):2232-2241. 10.4049/jimmunol.0900191</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0900191</ArticleId><ArticleId IdType="pmc">PMC3057032</ArticleId><ArticleId IdType="pubmed">19635906</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu A, Liu Y, Chen W, et al. . Tgf-&#x392;-induced regulatory T cells directly suppress B cell responses through a noncytotoxic mechanism. J Immunol. 2016;196(9):3631-3641. 10.4049/jimmunol.1501740</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1501740</ArticleId><ArticleId IdType="pmc">PMC4868785</ArticleId><ArticleId IdType="pubmed">27001954</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg SA, Lotze MT, Muul LM, et al. . Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313(23):1485-1492. 10.1056/NEJM198512053132327</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM198512053132327</ArticleId><ArticleId IdType="pubmed">3903508</ArticleId></ArticleIdList></Reference><Reference><Citation>Galleu A, Riffo-Vasquez Y, Trento C, et al. . Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Sci Transl Med. 2017;9(416):eaam7828.</Citation><ArticleIdList><ArticleId IdType="pubmed">29141887</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng L, Tang X, Zhou K, et al. . Microrna-663 induces immune dysregulation by inhibiting Tgf-&#x392;1 production in bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Cell Mol Immunol. 2019;16(3):260-274. 10.1038/cmi.2018.1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cmi.2018.1</ArticleId><ArticleId IdType="pmc">PMC6460486</ArticleId><ArticleId IdType="pubmed">30886422</ArticleId></ArticleIdList></Reference><Reference><Citation>Perico L, Morigi M, Rota C, et al. . Human mesenchymal stromal cells transplanted into mice stimulate renal tubular cells and enhance mitochondrial function. Nat Commun. 2017;8(1):983. 10.1038/s41467-017-00937-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00937-2</ArticleId><ArticleId IdType="pmc">PMC5754365</ArticleId><ArticleId IdType="pubmed">29042548</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>